The road to refractory graft-versus-host disease is paved with good intentions
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci177728 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Daniel North und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Refractory acute graft-versus-host disease (GVHD) occurs when the immune injury exceeds the capacity of injured tissues to regenerate and repair. While glucocorticoids have been used for decades to treat GVHD, Arnhold, Chang, and colleagues in this issue of the JCI question whether this approach can in fact be counterproductive. Using in vivo experimental models of GVHD and in vitro intestinal organoids, the study authors show that glucocorticoid exposure directly impeded small intestinal epithelial proliferation and survival, thus preventing the resolution of injury. These findings suggest that future treatment approaches for acute GVHD should include measures to reduce immune reactivity as well as interventions to actively promote tissue resilience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
North, D., & Chakraverty, R. (2024). The road to refractory graft-versus-host disease is paved with good intentions. Journal of Clinical Investigation. https://doi.org/10.1172/jci177728
Vancouver
North D, Chakraverty R. The road to refractory graft-versus-host disease is paved with good intentions. Journal of Clinical Investigation. 2024. doi:10.1172/jci177728
BibTeX
@article{North2024,
author = {North, Daniel and Chakraverty, Ronjon},
title = {The road to refractory graft-versus-host disease is paved with good intentions},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci177728}
}
EUVIMED